Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart) and Eli Lilly's Humalog (insulin lispro) – will be priced at no ...

This is what the The Boston Globe had to say about reforming PBMs: ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic version cost $99 for the same amount, according to the Biosimilars Council.

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...